Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRMD vs KURA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRMD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

CRMD Overall Winner 6-Pillar Tally: CRMD 5 – 1 KURA Matrix Metrics: CRMD 6 – 4 KURA

As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Kura Oncology, Inc. (KURA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CRMD carries a Unified Composite Score of 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin), whereas KURA carries 64.1/100 (BUY) at $7.30 (N/M Forward P/E, -394.3% operating margin).

  • Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (64.1/100 BUY vs. CRMD 53.2/100 HOLD), CRMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (41.0% vs. -394.3% operating margin) and revenue trajectory (-47.7% vs. +10.1% YoY).
  • Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile KURA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRMD vs KURA
CRMD NASDAQ Head-to-Head Winner
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap $384.7M
TTM Revenue $1.05B
Forward P/E 49.0x
Beta / 30D Vol 1.20β · 107% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 60.0 Fund 60.0 Flow 69.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.2%), weak momentum, RSI 29
RSI-14: 29.3 · SMA20: $6.32 · SMA50: $7.11
KURA NASDAQ
Kura Oncology, Inc.
Pharmaceutical Preparations
$7.30
-6.05% 1D
Market Cap $690.9M
TTM Revenue $79M
Forward P/E N/M
Beta / 30D Vol 1.42β · 108% Vol
Unified Composite Score
64.1 / 100 BUY
Tech 63.0 Fund 64.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.2%), weak momentum, RSI 35
RSI-14: 34.8 · SMA20: $8.86 · SMA50: $10.05

6-Pillar Scorecard Institutional Category Breakdown (CRMD 5 – 1 KURA)

Columns: Metric · CRMD · KURA
1. Valuation Multiples CRMD
Forward P/E 49.0x N/M
Trailing P/E 2.4x N/M
PEG Ratio 3.79x N/M
EV / Revenue N/M 8.3x
2. Growth & Scale KURA
Revenue Growth (YoY) -47.7% +10.1%
Earnings Growth (YoY) +6.7% +0.0%
TTM Revenue (USD) $1.05B $79M
Market Cap $384.7M $690.9M
3. Profitability & Quality CRMD
Gross Margin 87.4% N/A
Operating Margin 41.0% -394.3%
Net Profit Margin 15.5% 0.0%
Return on Equity (ROE) 15.3% -224.8%
4. Balance Sheet & Cash Flow CRMD
Cash Generation (TTM) $785M -$89M
Cash Flow Margin 74.6% -112.4%
Net Cash / Leverage $535M Net Cash $32M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRMD
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 56.3% (25th %ile) 103.8% (20th %ile)
Put/Call OI Skew 0.69x (Call-Skewed) 1.50x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat CRMD
OpEx & R&D Intensity 46.4% of Rev ($488M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRMD (6) vs KURA (4)
Institutional Metric CRMD KURA Criterion Row Edge
Market Capitalization
Scale
$384.7M $690.9M Larger Scale KURA
Trailing P/E Ratio
Valuation
2.4x N/M Lower Multiple CRMD
Forward P/E Ratio
Valuation
49.0x N/M Lower Multiple CRMD
Revenue Growth (YoY)
Growth
-47.7% +10.1% Higher Growth KURA
Operating Margin (TTM)
Profitability
41.0% -394.3% Higher Margin CRMD
Net Profit Margin
Profitability
15.5% 0.0% Higher Margin CRMD
Return on Equity (ROE)
Capital Efficiency
15.3% -224.8% Higher ROE CRMD
52-Week Range Position
Momentum
3% ($5–$13) 8% ($7–$14) Stronger Trend KURA
Beta / 30D Volatility
Risk Regime
1.20β · 107% Vol 1.42β · 108% Vol Lower Realized Risk CRMD
Unified Institutional Score
Composite Signal
53.2 / 100 (HOLD) 64.1 / 100 (BUY) Higher Composite KURA
Trailing 12M Revenue (USD)
Operating Scale
$1.05B $79M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.79x PEG · N/M EV/Rev N/M PEG · 8.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$785M ($535M Net Cash) -$89M ($32M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KURA +12.7 pp
CRMD: -32.3% · KURA: -19.6%
3M Horizon CRMD +0.95 pp
CRMD: -39.84% · KURA: -40.79%
6M Horizon KURA +17.21 pp
CRMD: -37.86% · KURA: -20.65%
1Y Horizon KURA +24.51 pp
CRMD: -56.16% · KURA: -31.65%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CRMD Revenue KURA Revenue CRMD Op. Margin KURA Op. Margin Margin Leader
FY2017 $0M N/A -9997.4% N/A CRMD
FY2018 $0M N/A -6250.4% N/A CRMD
FY2019 $0M N/A -7416.3% N/A CRMD
FY2020 $0M N/A -11378.4% N/A CRMD
FY2021 $0M N/A -15417.5% N/A CRMD
FY2022 $0M N/A -46819.9% N/A CRMD
FY2024 $40M $50M -51.4% -358.5% CRMD
FY2025 $310M $70M 48.2% -449.9% CRMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRMD BREAKDOWN
109d in phase · OBV DISTRIBUTION
Current IV 56.3%
IV Percentile 25th %ile
Put/Call OI Skew 0.69x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CRMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KURA BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 103.8%
IV Percentile 20th %ile
Put/Call OI Skew 1.50x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact KURA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRMD Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $384.7M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment 46.4% of Rev ($488M)
90D Engineering Disclosures 0 Published
KURA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $690.9M market capitalization and -394.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRMD vs KURA Key Questions & Quantitative Answers

As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Kura Oncology, Inc. (KURA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CRMD carries a Unified Composite Score of 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin), whereas KURA carries 64.1/100 (BUY) at $7.30 (N/M Forward P/E, -394.3% operating margin). Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (64.1/100 BUY vs. CRMD 53.2/100 HOLD), CRMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (41.0% vs. -394.3% operating margin) and revenue trajectory (-47.7% vs. +10.1% YoY). Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile KURA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KURA leads the Growth & Scale pillar: CRMD posts -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin), compared with KURA at +10.1% YoY revenue growth and +0.0% YoY earnings growth on $79M TTM revenue (N/A gross margin, -394.3% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), CRMD cumulative revenue shifted +675.0% while KURA shifted +40.0%. In operating R&D and SG&A reinvestment, CRMD deploys 46.4% of Rev ($488M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KURA.

CRMD screens cheaper on headline valuation multiples. CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin), whereas KURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.3x EV/Revenue (-112.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRMD (15.3% ROE) versus KURA (-224.8% ROE) capital efficiency.

In options market volatility and institutional positioning, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk). By comparison, KURA carries 103.8% implied volatility (20th %ile, Compressed (<25th %ile)), a 1.50x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 108% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.